Detalles de la búsqueda
1.
Evaluating predictive markers for viral rebound and safety assessment in blood and lumbar fluid during HIV-1 treatment interruption.
J Antimicrob Chemother
; 75(5): 1311-1320, 2020 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32053203
2.
Presence of CXCR4-using HIV-1 in patients with recently diagnosed infection: correlates and evidence for transmission.
J Infect Dis
; 205(2): 174-84, 2012 Jan 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-22147802
3.
Prevalence and epidemiology of HIV type 1 drug resistance among newly diagnosed therapy-naive patients in Belgium from 2003 to 2006.
AIDS Res Hum Retroviruses
; 24(3): 355-62, 2008 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-18327983
4.
Socio-economic, behavioural, (neuro)psychological and clinical determinants of HRQoL in people living with HIV in Belgium: a pilot study.
J Int AIDS Soc
; 16: 18643, 2013 Dec 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-24331754
5.
Impact of Delta 32-CCR5 heterozygosity on HIV-1 genetic evolution and variability--a study of 4 individuals infected with closely related HIV-1 strains.
Virology
; 379(2): 213-22, 2008 Sep 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-18692212
6.
Detection of drug resistance mutations as a predictor of subsequent virological failure in patients with HIV-1 viral rebounds of less than 1,000 RNA copies/ml.
J Med Virol
; 79(9): 1254-60, 2007 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-17607772
7.
Drug-resistant variants that evolve during nonsuppressive therapy persist in HIV-1-infected peripheral blood mononuclear cells after long-term highly active antiretroviral therapy.
J Acquir Immune Defic Syndr
; 35(5): 473-83, 2004 Apr 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-15021312
Resultados
1 -
7
de 7
1
Próxima >
>>